TNFRSF17 and breast carcinoma: BCMA CAR T-cell therapy is primarily applied to patients with BCMA-positive multiple myeloma (15), and HER2 CAR T-cell therapy is directed against breast cancer and other tumors with HER2 overexpression (16, 17).